HUMA•Humacyte will present research on its investigational bioengineered coronary bypass vessel at the American Heart Association Scientific Sessions in Chicago, Nov. 6-9, 2026, including a Phase 2a study design and preclinical results.
Humacyte will present coronary bypass research at the American Heart Association Scientific Sessions in Chicago, Nov. 6-9, 2026. CEO Laura Niklason will discuss engineering the microenvironment to accelerate vascular regeneration on Nov. 7.
A Nov. 7 presentation will outline the first-in-human Phase 2a study design for Humacyte's investigational bioengineered coronary bypass vessel. Preclinical coronary bypass results from porcine and ovine models will be presented Nov. 8.
